June 4, 2009

Marketing Trumps Safety: the case of Antipsychotics

Just as the FDA is convening an advisory committee hearing (June 9-10) about whether to expand the

Read More
Marketing Trumps Safety: the case of Antipsychotics

May 8, 2009

Has the Obama administration already cowered to the demands of Big Pharma?

The unexpected approval of a "me too" dangerous antipsychotic drug that the agency itself had deemed "NOT

Read More
Has the Obama administration already cowered to the demands of Big Pharma?

May 7, 2009

Title: FDA Approves Antipsychotic With Long History of Failure

"Hoechst Marion Roussel Inc. made initial inquiries into the drug; however, in May 1996, they discontinued research,

Read More
Title: FDA Approves Antipsychotic With Long History of Failure

March 30, 2009

Florida Antipsychotic Pre-Approval Requirement Protects PreschoolChildren

The State of Florida has established a pre-approval requirement to protect preschool children on Medicaid from being

Read More
Florida Antipsychotic Pre-Approval Requirement Protects PreschoolChildren

November 24, 2008

Biederman J & J Risperdal Documents

A group of internal emails by Johnson & Johnson officials-mostly from officials in the company’s Risperdal marketing

Read More
Biederman J & J Risperdal Documents

November 24, 2008

Biederman J & J Risperdal Documents

The New York Times reports (below) "Dr. Biederman’s work helped to fuel a 40-fold increase from 1994

Read More
Biederman J & J Risperdal Documents

November 18, 2008

Antipsychotic Use in Children: FDA Panel Rejects FDA Soft-Peddle Approach

The New York Times reports that an FDA advisory committee deliberating over the safety of using antipsychotic

Read More
Antipsychotic Use in Children: FDA Panel Rejects FDA Soft-Peddle Approach

November 30, 2007

Letter of Complaint to FDA Commissioner, 2007

                                 ALLIANCE FOR HUMAN RESEARCH PROTECTION   www.ahrp.org 142 West End Avenue, Suite 28P New York, NY

Read More
Letter of Complaint to FDA Commissioner, 2007

February 25, 2007

Activists Take on Eli Lilly Over Off-Label Marketing & Harm Caused by Zyprexa

Evelyn Pringle reports (below) that the group is also supporting Jim Gottstein in his battle with Eli

Read More
Activists Take on Eli Lilly Over Off-Label Marketing & Harm Caused by Zyprexa

January 12, 2007

Pfizer CEO Urges Staff to Mobilize & Lobby Congress Against Drug Price Controls

Below is a case example of the collision between Big Pharma and the American consumer. The New

Read More
Pfizer CEO Urges Staff to Mobilize & Lobby Congress Against Drug Price Controls

December 19, 2006

Lilly Marketing Zyprexa Challenged by Stat AGs–NYT_Antipsychotics: Off-label Use

The New York Times reports (below) that additional state Attorneys General are demanding that Eli "Lilly hand

Read More
Lilly Marketing Zyprexa Challenged by Stat AGs–NYT_Antipsychotics: Off-label Use

December 18, 2006

AHRQ No Evidence to Support Off-Label Uses of Atypical Antipsychotics

A new federally funded study by HHS Agency for Healthcare Research andQuality,  found little or no evidence

Read More
AHRQ No Evidence to Support Off-Label Uses of Atypical Antipsychotics

December 5, 2006

Assaultive Prescribing of Psych Drugs for Children

Suffer the little children for the drug companies and their duly financially awarded physicians, patient “advocacy” groups

Read More
Assaultive Prescribing of Psych Drugs for Children

December 1, 2006

New Schizophrenia Drugs No Better Than CheaperGenerics_Bloomberg_WashPost

The second phase of the government study, Clinical Antipsychotic Trials inIntervention Effectiveness (CATIE), was released and the

Read More
New Schizophrenia Drugs No Better Than CheaperGenerics_Bloomberg_WashPost